Immune-Modulating Cell Therapy for Preventing Beta-Islet Destruction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly Type 1 and Type 2, fail to effectively modulate the immune system to prevent the destruction of beta islets and associated cells, leading to autoimmune destruction and insulin dependence, with limited options for long-term prevention of complications.
Innovation Solution
Administration of perinatal cells, such as umbilical cord-derived mesenchymal stem cells, combined with T regulatory cells, to modulate the immune response, enhance beta islet cell survival, and promote insulin receptor sensitivity, using various administration methods and potentially encapsulating or genetically modifying these cells to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diabetes treatments are used, then blood glucose levels can be managed temporarily, but immune system destruction of beta islets continues unchecked leading to disease progression
Solution Approach 1:
The patent introduces immunomodulatory cells as intermediary agents that mediate between the immune system and beta islet cells. These cells suppress harmful autoimmune responses while preserving necessary immune function, preventing beta islet destruction without causing widespread immunosuppression. The immunomodulatory cells act as a bridge that reconciles the conflict between immune defense and autoimmunity.
Solution Approach 2:
The patent converts harmful autoreactive immune cells into beneficial immunomodulatory cells through a process called transdifferentiation. By exposing autoreactive T cells to specific antigens and cytokines, the treatment transforms cells that would normally attack beta islets into cells that protect them, turning the immune system's harmful potential into a therapeutic benefit.
2Productivity
If insulin therapy is administered to manage diabetes, then blood glucose control is achieved, but the underlying autoimmune process continues and complications develop
Solution Approach 1:
The patent applies preliminary action by intervening in the autoimmune process before complete beta islet destruction occurs. By administering immunomodulatory cells to patients with early-stage type 1 diabetes or at-risk individuals, the treatment prevents further islet cell loss and preserves endogenous insulin production, avoiding the need for lifelong insulin dependency and reducing long-term complications.
3Reliability
If immunosuppressive drugs are used to prevent organ rejection, then transplant survival improves, but non-specific immune suppression increases infection risk
Solution Approach 1:
The patent applies local quality by directing immunosuppression specifically to the pancreatic islet transplant site rather than causing systemic immunosuppression. The immunomodulatory cells and encapsulation devices create a localized immunoprivileged environment that protects the transplant from rejection while maintaining the recipient's overall immune competence, thereby preventing opportunistic infections.
Data Source
AI summary
Methods of reducing death, destruction or rejection of beta islets along with peripheral receptors in patients before they have diabetes, wherein said method comprising the steps of: a) obtaining a patient in need of immune cell therapy; b) administering to said patient one or more immunomodulatory cells; c) assessing the prevention and transition to diabetes.